

Table of Contents

[Presidential Welcome Letter](#) 2

[Introduction to ISSVA](#)..... 4

- About the World Congress
- 2024-2026 Board of Directors
- Scientific Committee
- Local Organizing Committee

[General Information and Hybrid Format](#) 5

[Continuing Medical Education](#)..... 6

[Venue Maps](#).....7

[Program at a Glance](#)..... 8

[Primer Day Schedule](#)..... 10

[Congress Schedule](#) 11

[Social Programs \(in-person only\)](#)..... 24

[Classification Session, Non-CME Symposia & Affiliate Meetings](#) 25

[Sponsors](#)..... 26

Presidential Welcome Letter

On behalf of the ISSVA Board, it is my great pleasure to welcome you to the ISSVA World Congress in Philadelphia.

The ISSVA World Congress is a unique moment for our community to come together: clinicians, researchers, allied health professionals, patient advocates, trainees, and industry partners, all united by a shared commitment to improving the lives of patients with vascular anomalies. It is a place where we exchange knowledge, challenge established thinking, build collaborations, and strengthen the international network that is so essential in a field as complex and rapidly evolving as ours.

Over recent years, we have witnessed remarkable progress in the understanding of vascular anomalies. Advances in genetics, molecular biology, imaging, interventional techniques, surgery, dermatology, hematology, oncology, pathology, and targeted therapies have changed the way we diagnose and treat many of these conditions. In particular, the emergence of new and repurposed medications offers exciting possibilities for patients who previously had limited therapeutic options.

At the same time, these developments also place an important responsibility on us. New therapies must be carefully and rigorously evaluated, not only to determine whether they are effective, but also to understand for whom they are appropriate, when they should be used, how they compare with established treatments, and how they can be integrated safely into long-term care. Innovation is essential, but it must go hand in hand with critical appraisal, careful follow-up, and a clear focus on meaningful benefits for patients.

Equally important, as we embrace new developments, we must continue to value and refine the therapies that already form the foundation of care for many patients. Embolization, sclerotherapy, surgery, laser therapy, compression therapy, medical management, supportive care, and long-term multidisciplinary follow-up all remain vital components of treatment. The future of vascular anomaly care will not be defined by one single therapeutic approach, but by our ability to combine existing and emerging options thoughtfully, evidence-based, and tailored to each individual patient.

This is why multidisciplinary collaboration remains at the heart of ISSVA. Vascular anomalies often cross traditional boundaries between specialties, organs, age groups, and healthcare systems. No single discipline can provide the full answer. The best care is delivered by teams that bring together complementary expertise, listen carefully to patients and families, and work collectively to select the right treatment, at the right time, for the right patient.

The scientific program in Philadelphia reflects this spirit. Through plenary sessions, abstract presentations, posters, debates, educational sessions, and informal discussions, we hope to create an environment that stimulates curiosity, encourages critical thinking, and supports

meaningful exchange across disciplines and generations. I encourage all participants to engage actively, ask questions, share experiences, and use this meeting to strengthen old collaborations and create new ones.

I would like to express my sincere gratitude to the Scientific Committee, the Planning Committee, our local hosts, the ISSVA Board, the EDI team, all speakers, moderators, abstract reviewers, sponsors, exhibitors, volunteers, and everyone who has contributed to making this Congress possible. Organizing a meeting of this scale requires many hours of work, thoughtful discussion, and dedication, and ISSVA is deeply grateful for these efforts.

Philadelphia is a fitting place for us to meet: a city with a rich medical, scientific, and historical tradition. I hope that, alongside the scientific program, you will also find time to reconnect with colleagues, welcome new members of our community, and enjoy the conversations that often become the starting point for future progress.

Welcome to the ISSVA World Congress in Philadelphia. I wish you an inspiring, productive, and memorable meeting.

Warmly,

Leo Schultze Kool
President, ISSVA

Introduction to ISSVA

The International Society for the Study of Vascular Anomalies (ISSVA) is a multidisciplinary, international organization of physicians, scientists, and health care providers dedicated to vascular anomalies. Its mission is to advance high-quality patient care through the promotion of clinical and scientific knowledge, education, and collaboration. ISSVA fosters the exchange of information through meetings, teaching programs, and the dissemination of classification systems and relevant scientific data.

About the World Congress

The International Society for the Study of Vascular Anomalies (ISSVA) emerged from biennial international workshops begun in 1976. As these meetings grew to include hundreds of specialists from diverse disciplines, they evolved into the World Congress, fostering long-standing collaboration, personal connections, and the exchange of scientific knowledge on vascular anomalies.

2024-2026 Board of Directors

Leo Schultze Kool, President
Juan Carlos Lopez-Gutierrez, President Elect
Francine Blei, Past President
Miikka Vikkula, Vice President
Denise Adams, Secretary
Maria Garzon, Treasurer

Dov Goldenberg, Scientific Committee Chair
Gresham Richter, Editor-in-Chief
Annouk-Anne Bisdorff, Member at Large
Eulalia Baselga, Member at Large
Michel Wassef, Member at Large

Scientific Committee

Dov Goldenberg (Chair)
Ionela Iacobas (Co-chair)
Ahmad Alomari
Eulalia Baselga
Isabel Colmenero
Gulraiz Chaudry
Anne Domp Martin
Ilona Frieden
Shoshana Greenberger

Adrienne Hammill
Juan Carlos Lopez-Gutierrez
Michio Ozeki
Thuy Phung
Tara Rosenberg
Emmanuel Seront
Sarah Sheppard
Miikka Vikkula
June Wu

Local Organizing Committee

- The Comprehensive Vascular Anomalies Program
- The Jill and Mark Fishman Center for Lymphatic Disorders
- CHOP Marketing and Public Relations

With special thanks to: Denise Adams, Arlene Ambrosine, Allison Britt, Melissa Casey, Sally Cohen-Cutler, Mike Fox, Meg Maguire, Kathleen Rooney, Tim Tillson, James Treat and Anne Marie Cahill

General Information and Hybrid Format

General Information & Travel

The ISSVA World Congress: The Latest in Vascular Anomalies is ISSVA's biannual Congress, which is attended by a wide array of specialists including intervention radiologists, dermatologists, plastic surgeons, ENT surgeons, pediatricians, pediatric surgeons, oncologists and pathologists, presents the latest developments in this fast-moving area.

Entry into the United States

The United States government has different requirements for entry based on the country you are traveling from. In addition to your passport, you may also require a visa. Advance travel planning and early visa application are important and up to you. Guidelines are changing rapidly; please make sure you do your research.

Philadelphia, PA, United States

Philadelphia is the birthplace of the United States, and America's first UNESCO World Heritage City. It is known for its **arts, culture, cuisine, and colonial and Revolutionary-era history**. It will be an exciting opportunity for professionals in the field of vascular anomalies to gather and exchange knowledge, underscoring the importance of global collaboration and innovation in addressing vascular anomalies.

Time Zone

Philadelphia is in the Eastern Time Zone time zone during the World Congress.

Venue

The ISSVA World Congress is being held at the Philadelphia Marriott Downtown, which is located at 200 Filbert Street, Philadelphia, Pennsylvania, USA, 19107. The venue is roughly 30 minutes from the Philadelphia International Airport.

Virtual Meeting Website

The virtual meeting will be hosted by our onsite AV company, which will be accessible to anyone who registered for the virtual programming. This platform will offer live talks during the Scientific Program. You will receive an email with your login instructions prior to the start of the ISSVA World Congress.

Recorded Content

All sessions will be recorded and available to all attendees (in-person and virtual) after the World Congress. Once posted, you will receive an email with instructions and recordings will be available for at least 30 days (once available).

Continuing Medical Education Credits

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and International Society for the Study of Vascular Anomalies. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



Physicians (ACCME) Credit Designation

Amedco LLC designates this live activity for a maximum of 28.50 *AMA PRA Category 1 Credits* for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Claiming CMEs

How to Get Your Certificate

1. Go to issva.cmecertificateonline.com
2. Click on the 2026 ISSVA World Congress link.
3. Evaluate the meeting.
4. Print, download, or save your certificate for your records.
5. If you lose your certificate, or need help, go to help.cmecertificateonline.com

[Click here to access the 2026 Learner Notification.](#)


Venue Maps

Level 5

- Registration (EF Lobby)
- Plenary (Salon EF)
- Symposiums (Salon CD)


Level 4

- Speaker Ready Room (403)
- Exhibitors (Franklin B)
- Posters (Franklin B)
- Breaks/Lunch (Franklin B)



Franklin Hall B

Level 4 – Exhibits, Catering, and Posters



401 – Meeting Room	403 – Meeting Room	404- Speaker Ready Room
--------------------	--------------------	-------------------------

Program at a Glance

Tuesday, 19 May - Primer Day		
TIME	SESSION TITLE	ROOM
Schedule		
08:00 – 10:00	Welcome and Primer Day AM Session I	Salon EF
10:00 – 10:30	Coffee Break	Franklin B
10:30 – 12:30	Primer Day AM Session II	Salon EF
12:30 – 14:00	Lunch Break Classification Session	Franklin B Salon CD
14:00 – 16:00	Primer Day Session - Innovation and Outcomes in Complicated Lymphatic Anomalies (CHOP)	Salon EF
16:00 – 16:30	Coffee Break	Franklin B
16:30 – 18:00	Difficult Case Panel Discussion	Salon EF
Welcome Reception		
18:00 – 19:30	<i>Welcome Reception</i>	Franklin B

Wednesday, 20 May – Scientific Sessions		
TIME	SESSION TITLE	ROOM
Schedule		
7:00 - 8:00	Non-CME Breakfast Symposium – Relay Therapeutics	Salon CD
8:00 - 10:00	Session 1: Tumors	Salon EF
10:00 - 10:30	Coffee Break	Franklin B
10:30 - 12:00	Session 2: AVM I	Salon EF
12:00 - 12:35	The John B Mulliken Keynote Lecture: Taija Mäkinen - From Vascular Development and Models to Disease: Guiding New Approaches to Vascular Malformations	Salon EF
12:35 - 14:00	Lunch Break Poster Session Non-CME Lunch Symposium – Novartis	Franklin B Franklin B Salon CD
14:00 - 16:00	Session 3: AVM II	Salon EF
16:00 - 16:30	Coffee Break	Franklin B
16:30 – 17:00	Late Breaking Abstract Session	Salon EF
17:10 - 17:40	Dr John B Mulliken Tribute	Salon EF
17:40 - 18:10	<i>General Assembly (ISSVA Members Meeting)</i>	Salon EF

Thursday, 21 May – Scientific Sessions		
TIME	SESSION TITLE	ROOM
Schedule		
7:00 - 8:00	Non-CME Breakfast Symposium – Protara Therapeutics	Salon CD
08:00 - 10:00	Session 4: Other Studies in Vascular Anomalies I	Salon EF
10:00 - 10:30	Coffee Break	Franklin B
10:30 - 12:30	Session 5: Lymphatics	Salon EF
12:30 - 14:00	Lunch Break Poster Session	Franklin B Franklin B
12:30 – 13:30	Non-CME Lunch Symposium – Palvella Therapeutics	Salon CD
14:00 - 16:00	Session 6: Venous	Salon EF
16:30 - 17:00	Coffee Break	Franklin B
16:30 - 18:00	Session 7: Capillary	Salon EF
Congress Social Event (ticket required)		
19:00 - 22:00	Congress Social Event – Reading Terminal Market	Off-site

Friday, 22 May – Scientific Sessions		
TIME	SESSION TITLE	ROOM
Schedule		
06:30 - 07:30	ISSVA Running Club (pre-registration required)	Off-site
08:00 - 10:00	Session 8: Other Studies in Vascular Malformations II	Salon EF
10:00 - 10:30	Coffee Break	Franklin B
10:30 - 12:30	Session 9: Combined	Salon EF
12:30 - 14:00	Lunch Break Poster Sessions	Franklin B Franklin B
14:00 - 16:00	Session 10: Difficult Cases	Salon EF
Following Presentations	Closing Ceremony	Salon EF

OPENING HOURS:

	Registration (Salon EF Lobby)	Speaker Resource Room (Room 404)	Exhibit Hall (Franklin B)
Monday, 18 May	16:30 – 19:00	16:30 – 18:30	
Tuesday, 19 May	07:00 - 19:00	07:00 - 18:00	10:30 - 19:30
Wednesday, 20 May	07:00 - 18:30	07:00 - 18:00	10:30 - 16:30
Thursday, 21 May	07:00 - 18:00	07:00 - 18:00	10:30 – 16:30
Friday, 22 May	07:00 - 16:00	07:00 - 16:00	10:30 - 14:00

Primer Day Sessions

All session and presentation times are in **local time**. Presenters are subject to change.

Tuesday, 19 May 2026 – Primer Day

Session 1 – 8:00-10:00 AM – AM Primer Day Session

Moderators – Kristina Rosbe, Paolo Gasperella

- 8:00** Introduction and Welcome | ISSVA Board of Directors
- 8:10** ISSVA Classification | Dov Goldenberg (Brazil)
- 8:25** Infantile Hemangioma - Diagnosis, Associations, Management | Eulalia Baselga (Spain) and Maria Garzon (United States)
- 8:54** KHE | Alexandra Borst (United States)
- 9:10** Liver Hemangioma & Other Tumors | Ionela Iacobas (United States) and Patricia Burrows (United States)
- 9:25** OBGYN Concerns/Prenatal Management | Beth Schwartz (United States)
- 9:40** Pathology of Vascular Anomalies | Thuy Phung (United States)

Session 2 – 10:30-12:30 – AM Primer Day Session

Moderators – Ewa Bien, Francine Blei

- 10:30** Genetics of Vascular Malformations | Sarah Sheppard (United States)
- 10:47** Arteriovenous Malformations | Henar Cuervo (Spain)
- 11:04** Lymphatic Malformations | Sally Cohen-Cutler (United States)
- 11:21** Patient Organizations and Networks - The EU and USA Perspective | Caroline Van den Bosch (Netherlands) and Mellene Finger (United States)
- 11:38** Vascular Malformations – Imaging and IR | Anne Marie Cahill (United States)
- 11:55** Vascular Malformations – Surgical Options | Ann Kulungowski (United States)
- 12:12** Vascular Malformations – Medication Options | Emmanuel Seront (Belgium)

Session 3 – 14:00-16:00 – Innovation and Outcomes in Complicated Lymphatic Anomalies

Moderator: Denise Adams

- 14:00** Basic Science Discoveries - GSD | Michael Dellinger (United States)
- 14:13** Genomics; Latest Outcomes with New Techniques | Hakon Hakonarson (United States)
- 14:26** A Conundrum.... Lack of genotype. When the phenotypes do not fit the genotype. How do we approach medical therapies? | Sally Cohen-Cutler (United States)
- 14:36** Surgical Interventions: When, What, and Outcomes | Pablo Laje (United States)
- 14:49** Innovative Diagnostics for CCLAs and Innovative Interventional Approaches with Outcome Data | Abhay Srinivasan (United States)
- 15:02** The GI Approach | Naylor Brownell (United States)
- 15:15** Panel - Case Presentation | All from session, plus - Allison Britt, Melanie Savoca, Erin Pinto, Meg Maguire, Kathleen Rooney, Megan Perez

Session 4 - 16:30-18:00 – Difficult Cases

Moderator – Sheilagh Maguiness, Taizo Nakano, Tony Pennington

Cases

- Non-Immune Hydrops Fetalis as an Initial Presentation of PIK3CA-Related Overgrowth Syndrome: A Case Consistent with Megalencephaly-Capillary Malformation | Margaret Cote (United States)

- Successful use of alpelisib in a young infant with a massive cervicofacial lymphatic malformation | Michael Fox (United States)
- BRAF Mutation in Eruptive Pyogenic Granuloma-Like Lesions Developing Over Vascular Anomaly | Shannon Wessel (United States)
- Recurrent bright red blood per rectum in an infant with PIK3R1 variant | Allison Miller (United States)

Congress Program

All sessions and presentation times are in the **local time**. Presenting author is underlined; presenters are subject to change.

Wednesday, 20 May 2026 – Scientific Sessions

7:00 - 8:00 – Sponsored Breakfast Symposium – Relay Therapeutics

Session 1 – Tumors - 8:00-10:00

Moderators: Anne Dompmartin, Dario Teplisky

8:00 Infantile hemangiomas in preterm infants: high-risk clinical features and increased treatment requirement with comparable beta-blocker safety | Flora Bradley (United States), Esteban Fernandez-Faith (United States), Final Patel (United States), Aisa Longnecker (United States), Kristen Holland (United States), Anthony Mancini (United States), Sonal Shah (United States), Deepti Gupta (United States), Elena Pope (Canada), Maria Garzon (United States), Catherine McCuaig (Canada), Erica Dale (United States), Megha Tollefson (United States), Amy Buros Stein (United States), Eulalia Baselga Torres (Spain), Ilona Frieden (United States)

8:10 Glutamine Addiction Rewires the Glutamine-Asparagine Axis to drive Endothelial Proliferation and Angiogenesis in Infantile Hemangioma | Tong Qiu (China), Yi Ji (China)

8:20 Germline SOX18 Mutation in an Infant with Multifocal Cutaneous and Visceral up | Iksha Kumar (United States), Amy Bezold (United States), Claire Kaufman (United States), Melinda Wu (United States), Gary Nesbit (United States), Andrew Phelps (United States), Carol MacArthur (United States), Alison Small (United States)

8:30 Scalp infantile hemangioma regression rate and effect on hair follicle: a long-term follow-up | Jingjing Sun (China), Shih-Jen Chang (China), Rui Chang (China), Qianyi Chen (China), Lei Chang (China), Yajing Qiu (China), Xiaoxi Lin (China)

8:40 Breast Region Infantile Hemangiomas: clinical presentation, outcome pathway and therapeutic challenge | Anne Dompmartin (France), Lea Frigout (France), Valérie Dekeuleneer (Belgium), Laurence M Boon (Belgium), Jean Matthieu L'Orphelin (France)

8:50 The successful use of a minimally invasive temperature-controlled Radio Frequency (RF) device to treat recalcitrant symptomatic hemangiomas in children | Kevin Hopkins (United States), Vanessa Dimas (United States), Yongxu (Joyce) Huang (United States)

9:00 Infantile Hemangiomas that Don't Read the Textbook: Unexpected Outcomes in Adolescents and Adults | Final G. Patel (United States), Ilona J. Frieden (United States), Adrienne Hammill (United States), Erin Mathes (United States), Mitchell Braun (United States), Maria Laura Cossio Traverso (Chile), Esteban Fernandez Faith (United States), Deepti Gupta (United States), Cheryl Bayart (United States), Hemangioma Investigator Group

- 9:10 Complicated Vascular Tumors: Evaluating Diagnostic Concordance Among Clinical, Imaging, and Pathologic Findings** | [Miriam Meghnagi \(United States\)](#), Helen Zhou (United States), Elizabeth Ward (United States), Anish Raman (United States), Erona Shurdhiqi (United States), Seth E. Vatsky (United States), Portia A. Krieger (United States), Cassandra A. Ligh (United States)
- 9:20 Angiopoietin-2 promotes invasion and angiogenesis in kaposiform haemangioendothelioma** | [Yuru Lan](#) (China), Jiangyuan Zhou (China), Tong Qiu (China), Yi Ji (China)
- 9:30 Kaposiform Hemangioendothelioma (KHE) Beyond Infancy: Clinical and Radiologic Characteristics** | [Anne Sailer \(United States\)](#), Christine Boone (United States), Sean Schoeman (United States), Biniyam Tabor (United States), Jasmine Steele (United States), Melissa Casey (United States), Seth Vatsky (United States), Abhay Srinivasan (United States), Denise Adams (United States), Anne Marie Cahill (United States)
- 9:40 Cryotherapy with CryoPen® versus Surgical Excision for Pediatric Pyogenic Granuloma: A Prospective Nonrandomized Clinical Trial** | [Christina Flucher \(Austria\)](#), Paolo Gasparella (Austria), Margarita Eibisberger (Austria), Selina Doppler (Austria), Emir Q. Haxhija (Austria)
- 9:50 Examining Ulceration in Infantile Hemangiomas: Are Black Patients at Risk for More Severe Presentations?** | [Aisa Longnecker \(United States\)](#), Esteban Fernández Faith (United States), Flora E. Bradley (United States), Ilona J. Frieden (United States), Anthony J. Mancini (United States), Catherine McCuaig (Canada), Final Patel (United States), Sonal D. Shah (United States), Amy B. Stein (United States), Megha M. Tollefson (United States), Kristen E. Holland (United States)

Session 2 - AVM 1 – 10:30-12:00

Moderators: Alexandra Borst, Julien Coulie

- 10:30 Hierarchical Micro-Nano Cascade Delivery for Precise and Durable Molecular Therapy of Diffuse Extracranial AVMs** | [Xiangyi Wu \(China\)](#), Ren Kai (China), Hao Gu (China), Jiannan Liu (China), Jiaxue Zhu (China), Xindong Fan (China), Lixin Su (China), Haoyang Xv (China)
- 10:40 Beyond the RAS/MAPK Pathway: A Novel PIK3CA-Linked High-Flow Spinal AVM** | [Iksha Kumar \(United States\)](#), Alison Small (United States), Gary Nesbit (United States), Marco Colasurdo (United States), Claire Kaufman (United States), Melinda Wu (United States)
- 10:50 Pediatric Presentations of HHT and CM-AVM** | Bridget Condit (United States), Raj Kasthuri (United States), Karen Smith (United States), Zahra Girnary (United States), Clara Hildebrandt (United States), Elizabeth Nieman (United States), Sawyer Everett (United States), [Alexandra Borst \(United States\)](#)
- 11:00 Capillary Malformation-Arteriovenous Malformation Syndrome Associated with Gastrointestinal Neuroendocrine Tumor: A Report of Two Cases** | Beatriz Cáceres-Nazario (United States), [Elizabeth Nieman \(United States\)](#), Clara Hildebrandt (United States), Raj Kasthuri (United States), Karen Smith (United States), Sheng-Che "Alex" Hung (United States), Simon Gray (United States), Julie Blatt (United States), Bridget Condit (United States), Alexandra Borst (United States)
- 11:10 Retrospective Single-Center Study on the Association Between Pregnancy and Extracranial Arteriovenous Malformations** | [Julien Coulie \(Belgium\)](#), Emmanuel Seront (Belgium), Wendy Nicaise (Belgium), Gabriele Ciccio (Belgium), Stanislas Smajda (Belgium), Frank Hammer (Belgium), Miikka Vikkula (Belgium)

- 11:20 Trametinib for the Treatment of Complicated Extracranial Arteriovenous Malformations** | [Chaw Ning Lee \(United States\)](#), Ramrada Lekwuttikarn (United States), Ali B Syed (United States), Jordan Kim Uyen Bui (United States), Thomas Buschbacher (United States), Huy M. Do (United States), Joyce M. C. Teng (United States)
- 11:30 A Phase II Trial of Cobimetinib in Patients with Extracranial Arteriovenous Malformations** | [Joanna Mack \(United States\)](#), Kumar Shashi (United States), Shelley Crary (United States), Hannah Price (United States), Graham Strub (United States), Gresham Richter (United States), Robert Buchmann (United States), David Becton (United States), Jeremy Sabado (United States), Kevin Bielałowicz (United States)
- 11:40 Precision Medicine Approach to Arteriovenous Malformations: cfDNA-Based Diagnostics Enable Effective Targeted Therapy** | [Ren Cai \(China\)](#), Xitao Yang (China), Hao Gu (China), Xiangyi Wu (China), En Zhou (China), Yifeng Han (China), Yi Sun (China), Lixin Su (China), Cong Huai (China), Shengying Qin (China), Lin He (China), Xindong Fan (China), Jiannan Liu (China), Xiaolin Wang (China), Jiaxue Zhu (China)
- 11:50 Scientific Committee Talk** | Dov Goldenberg and Ionela Iacobas
- 12:00 Introduction - The John B. Mulliken Keynote Lecture** | Dov Goldenberg
- 12:05 The John B. Mulliken Keynote Lecture: Taija Mäkinen - From Vascular Development and Models to Disease: Guiding New Approaches to Vascular Malformations**

12:35 Lunch and Posters (85 min)

12:35-13:35 – Sponsored Lunch Symposium – Novartis

Session 3 - AVM 2 – 14:00 - 16:00

Moderators: Ahmad Alomari, Annouk Bisdorff-Bresson

- 14:00 Hereditary hemorrhagic telangiectasia in pediatrics: Clinical characteristics, imaging findings, and genetic mutations** | [Abdallah Al-Ani \(United States\)](#), Timothy Klouda (United States), Tishi Shah (United States), Melisa Ruiz-Gutierrez (United States), Aya Abu El Haija (United States), Mohammad Amarneh (United States), Gulraiz Chaudry (United States), Raja Shaikh (United States), Horacio Padua (United States), Kyung Kim (United States), Ahmad Alomari (United States), Josee Dubois (United States), Marilyn Liang (United States), Maureen Hohl (United States), Bridget DeYoung (United States), Erin Spera (United States), Kaycee Carbone (United States)
- 14:10 Hepatic Involvement in Patients with Hereditary Hemorrhagic Telangiectasia: A Cross Sectional Study from a Referral Center** | [Marcelo Serra \(Argentina\)](#), Alanis Szyferman (Argentina), Kira Grimberg (Argentina), Rodolfo Trinidad Torres Aray (Argentina), Luca Caratti (Argentina), Julia Udaquiola (Argentina), Juan Carlos Bandi (Argentina), Ana Braslavsky (Argentina)
- 14:20 Single-Center Experience in Interventional Therapy for Congenital Portosystemic Shunts in Children** | Xiangfeng Guo (China), Qi Di (China), Sanlin Li (China), Yuhao Jiao (China), Chenghao Chen (China), Longfei Liu (China), Ge Liu (China), [Gang Shen \(China\)](#)
- 14:30 Take 2: Techniques for re-intervening on pelvic AVMs with prior proximal embolization** | [Monica Matsumoto \(United States\)](#), Camden De Sanctis (United States), Alexander Ushinsky (United States), Ryan Cobb (United States)
- 14:40 De Novo Development of Arteriovenous Malformations Following Lateral Marginal Vein Thrombosis in Klippel-Trenaunay Syndrome: A Three-Patient Case Series** | [Monica Matsumoto \(United States\)](#), Sang Yub Lee (South Korea)
- 14:50 Intraneural Arteries in Arteriovenous Malformations: Their Role in Neurological**

Symptoms | Ahmad Alomari (United States)

15:00 Periorbital Arteriovenous Malformation Treated by Genotype Guided Trametinib
| Hao Gu (China), Xindong Fan (China), Lixin Su (China), Jiaxue Zhu (China), Ren Cai (China)

15:10 Direct Puncture of the Left Inferior Alveolar Vein for Embolization of a Mandibular Arteriovenous Malformation | Brennan Cook (United States), Raufay Abbasi (United States), Daniel Valdivia (United States), Nemanja Novakovic (United States), Srihari Sundararajan (United States), Gaurav Gupta (United States), Joe Vella (United States), Phil Engel (United States), Susan Murphy (United States), Sudipta Roychowdhury (United States)

15:20 Giant cervical AVM in a child with Bannayan-Riley-Ruvalcaba syndrome (BRRS)
| Shiro Onozawa (Japan), Hideki Mori (Japan), Kunie Ouchi (Japan), Yuki Takara (Japan), Ryosuke Miyauchi (Japan), Naoki Fukuyama (Japan), Toyohisa Miyata (Japan), Takanori Kochi (Japan), Takuya Kitamura (Japan), Shirabe Matsumoto (Japan), Yosuke Yamamoto (Japan), Suguru Hitomi (Japan), Tatsuro Murakami (Japan), Asami Tozawa (Japan)

15:30 Modified Electro Sclero Therapy (MEST) + Surgery. The ideal treatment for diffuse, disfiguring, facial AVM with hypertrophy? | Giacomo Colletti (Italy), Linda Rozell-Shannon (United States), Sara Negrello (Italy)

15:40 A Highly Complex Cervico-Occipital High-Flow Vascular Malformation in a PTEN-PHOST Patient: Multistage Endovascular, Surgical, and Medical Management
| Nicolas Affranchino (Argentina), Dario Teplisky (Argentina), Natalia Torres Huamani (Argentina), Luciano Korman (Argentina), Laura Gonzalez (Argentina), Flavio Requejo (Argentina)

15:50 Analysis of Outcome and Adverse Events after Peripheral Arteriovenous Malformation Embolization: Single Korean Referral Vascular Anomalies Center 20 years-Experience | Sang Yub Lee (South Korea), Kwang Bo Park (South Korea), Young Soo Do (South Korea), Shin Seok Yang (South Korea), Hee Young Ju (South Korea)

16:30 – Late Breaking Abstract Session

Moderators: Dov Goldenberg

16:30 QTORIN™ Rapamycin Topical 3.9% Anhydrous Gel: Statistically Significant, Clinically Meaningful Improvement in Microcystic Lymphatic Malformations (Phase 3 SELVA) and Cutaneous Venous Malformations (Phase 2 TOIVA) | James Treat

16:35 Long-Term Safety and Efficacy of Alpelisib in PIK3CA-Related Overgrowth Spectrum: Updated Results from the EPIK-P3 Study | Guillaume Canaud

16:40 Efficacy, Safety, and Pharmacokinetics of Alpelisib in Pediatric and Adult Patients With PIK3CA-Related Lymphatic Malformations: EPIK-L1 Phase 2 Study Stage 1 Results | Denise Adams

16:45 Initial Results of Zovegalisib (RLY-2608), a Mutant-selective PI3K α inhibitor in Adult and Pediatric Patients with PIK3CA-Driven Vascular Malformations | Bryan Sisk

16:50 Timolol Maleate Gel for Proliferative Superficial Infantile Hemangioma: A multicenter, randomized, double-blind, placebo-controlled phase II/III trial | Yajing Qui

16:55 Early Central Nervous System Screening in Capillary Malformation–Arteriovenous

Malformation Syndrome: A Multicenter Retrospective Study of 94 Asymptomatic Children | Marta Ivars

Break – 10 minutes

17:10 – 17:40 – John B. Mulliken Tribute - *Presenters: Miikka Vikkula, Laurence Boon, and Steven Fishman*

17:45 – General Assembly (ISSVA Member Meeting) | *ISSVA Board of Directors*

Thursday, 21 May 2026 – Scientific Sessions

7:00 - 8:00 – Sponsored Breakfast Symposium – Protara Therapeutics

Session 4 - Other Studies 1 – 8:00-10:00

Moderators: Tara Rosenberg, Thuy Phung

- 8:00 EPHB4 mutations cause CM-AVM2, Central Conducting Lymphatic Anomalies, Vein of Galen malformations, and other vascular anomalies: Widening the Clinical Spectrum of Phenotypic Expression** | [Final Patel \(United States\)](#), Flora E. Bradley (United States), Deepti Gupta (United States), Brandi Kenner-Bell (United States), Maria Cordisco (United States), Beth Apsel Winger (United States), Sarah Chamlin (United States), Maanasa Indaram (United States), Joseph Sheih (United States), James Bennett (United States), Zoe Nelson (United States), Erin Mathes (United States), Ilona J. Frieden (United States)
- 8:10 Loss of Function of FZD6 Causes Central Conducting Lymphatic Anomaly and Possibly Sensorineural Hearing Loss** | [Luciana Garlisi Torales \(United States\)](#), Evalyn Beall (United States), Young-In Chi (United States), Christopher Marshall (United States), Christoph Seiler (United States), Michael March (United States), Leticia Matsuoka (United States), Ferdous Abdulwahab (Saudi Arabia), Mohammad Badran (Saudi Arabia), Hanan Shamseldin (Saudi Arabia), Lukas Ryba (Czech Republic), Marcela Malikova (Czech Republic), Tamas Revay (Canada), Francois Bernier (Canada), Julie Lauzon (Canada), Micheil Innes (Canada), Matthew Deardoff (United States), Fowsan Alkuraya (Saudi Arabia), Raul Urrutia (United States), Maureen Cetera (United States), Sarah Sheppard (United States)
- 8:20 Pathogenic PIK3CA variants induced proteasome insufficiency and VE-CADHERIN and CD31 proteostasis defects in Lymphatic Malformations** | [Nour Bacha \(United States\)](#), Benjamin Kheyfets (United States), Samantha Rosen (United States), June K Wu (United States), Carrie J Shawber (United States)
- 8:30 Integrin- $\alpha 9$ in oncogenic PI3K-driven lymphatic malformations: a key player in disease recurrence?** | [Sandra Castillo \(Spain\)](#), Alba Albinyà (Spain), Ana Angulo-Urarte (Spain), Sonia Paco (Spain), Camilo Alarcón (Spain), Carlota Rovira (Spain), Marta Ivars (Spain), Miguel Bejarano (Spain), Cinzia Lavarino (Spain), Eulalia Baselga (Spain), Mariona Graupera (Spain)
- 8:40 Establishment of Patient-Derived Endothelial Cell Models of Kaposiform Hemangioendothelioma for Mechanistic Studies and Therapeutic Screening** | [Jiangyuan Zhou \(China\)](#), Yi Ji (China)
- 8:50 Novel RAS Inhibitor RMC7977 Blocks Vascular Overgrowth of NRASQ61R Mutant**

Endothelial Cells | [Sara Alharbi \(United States\)](#), Svatava Merkle (United States), Patricia Pastura (United States), Griffin McDaniel (United States), Tim Le Cras (United States)

9:00 Safety and efficacy of percutaneous core needle biopsy of vascular anomalies | Eleanor Kim (United States), Aya Abu El Haija (United States), Alyaa Al-Ibraheemi (United States), Ahmad Alomari (United States), Gulraiz Chaudry (United States), Kaycee Carbone (United States), Josee Dubois (United States), Maureen Holh (United States), Emalyn Johnson (United States), Kyung Kim (United States), Harry Kozakewich (United States), Marilyn Liang (United States), Horacio Padua (United States), Melisa Ruiz-Gutierrez (United States), Tishi Shah (United States), Raja Shaikh (United States), Mohammad Amarneh (United States)

9:10 Metabolic Effects of Two-Year Sirolimus in Adult Vascular Malformations: A VASE Sub Analysis | [Emmanuel Seront \(Belgium\)](#), An Van Damme (Belgium), Annouk Bisdorff-Bresson (France), Anne Domp Martin (France), Marie-Antoinette Sevestre Pietri (France), Isabelle Quere (France), Rune Andersen (Norway), Miikka Vikkula (Belgium), Laurence Boon (Belgium)

9:20 Response to alpelisib in patients who did not respond to sirolimus | [Marina Heskel \(United States\)](#), Deeti Pithadia (United States), Patricia Cornett (United States), Arman Shotayev (United States), Erin Mathes (United States), Josephine Czechowicz (United States), Ilona Frieden (United States), Beth Apsel Winger (United States)

9:30 Revisiting live vaccine contraindications under mTOR inhibition: insights from a measles outbreak in patients treated with sirolimus. | [Emma Kocsis Derfalvi \(Canada\)](#), Beata Derfalvi (Canada), Pamala Cox (Canada), Meghan Pike (Canada), Victoria Price (Canada)

9:40 Impact of Vascular Malformations on Women's Health: Results from the Survey of Women with vascular Anomalies (SWAN) Study | [Elissa Engel \(United States\)](#), Hannah Hayward (United States), Taryn Wassmer (United States), Kiersten Ricci (United States), Lesley Breech (United States), Adrienne Hammill (United States)

9:50 Visible and Invisible Burdens: The Psychosocial Impact of Vascular Malformations in Adolescence | [Lauren Hill \(United States\)](#), Ann Kulungowski (United States), Jacqueline Jones (United States), Aparna Annam (United States), Lauren Larroque (United States), Taizo Nakano (United States)

10:00 Break

Session 5 - Lymphatics – 10:30-12:30

Moderators: Paloma Triana, Sarah Sheppard

10:30 Biallelic variants in ITGA9 cause recessive central conducting lymphatic anomaly with nonimmune hydrops fetalis | [Micheal March \(United States\)](#), Christoph Seiler (United States), Charlotte Andersen (Denmark), Kristian Assing (Denmark), Tugba Kalayci (Turkey), Adeline Bonnard (France), Joel Leddbetter (United States), Matthew Kreth (United States), Allison Britt (United States), Nora O'Connor (United States), Sarah Sheppard (United States), Erin Pinto (United States), Denise Adams (United States), Christopher Smith (United States), Yoav Dori (United States), Hakon Hakonarson (United States), Dong Li (United States)

10:40 NRAS^{Q61R} expression in lymphatic endothelial cells causes enlarged vessels, hemorrhagic chylous effusions, and high mortality in a mouse model of kaposiform lymphangiomatosis | [C. Griffin McDaniel \(United States\)](#), Patricia Pastura

- (United States), Joshua P. Scallan (United States), Timothy D. Le Cras (United States)
- 10:50 Pathogenic variants in RIT1 cause central conducting lymphatic anomaly** | [Lola Zerbib \(United States\)](#), Yoav Dori (United States), Dong Li (United States), Michael March (United States), Jessica Johnson (United States), Christopher Marshall (United States), Benjamin Sempowski (United States), Catherine McInerney (United States), Sarah Sheppard (United States)
- 11:00 Somatic in-frame duplication and insertion variants in the switch II region of three RAS genes cause complex lymphatic anomalies** | [Dong Li \(United States\)](#), Michael March (United States), Christoph Seiler (United States), Fengxiang Wang (United States), Nora O'Connor (United States), Alexandria Thomas (United States), Allison Britt (United States), Erin Pinto (United States), Lauren Biroc (United States), Ganesh Krishnamurthy (United States), Pablo Laje (United States), Alexandra Borst (United States), Sally Cohen-Cutler (United States), Seth Vatsky (United States), Janet Reid (United States), Abhay Srinivasan (United States), Anne Marie Cahill (United States), Michael Fox (United States), Sarah Sheppard (United States), Denise Adams (United States), Christopher Smith (United States), Yoav Dori (United States), Hakon Hakonarson (United States)
- 11:10 Sirolimus Is More Effective Than Alpelisib in Blocking Vascular Overgrowth of NRAS Q61R Mutant Endothelial Cells in Cell Culture and Xenograft Models of Kaposiform Lymphangiomatosis** | [Svatava Merkle \(United States\)](#), Sara Alharbi (United States), Patricia Pastura (United States), C.Griffin McDaniel (United States), Timothy D. Le Cras (United States)
- 11:20 20S proteasome inhibitors as a novel therapy for lymphatic and venous malformations** | [Nour C Bacha \(United States\)](#), Noa Shapiro Franklin (United States), Joseph D McCarron (United States), June K Wu (United States), Carrie J Shawber (United States)
- 11:30 Generalized Lymphatic Anomaly due to a gene Fusion Responsive to Sirolimus Treatment** | Pascal Brouillard (Belgium), Manon Le Roux (Belgium), Nassim Homayun-Sepehr (Belgium), Dana Dimitriu (Belgium), An-Katrien De Roo (Belgium), Nicole Revencu (Belgium), An Van Damme (Belgium), Laurence M. Boon (Belgium), [Miikka Vakkula \(Belgium\)](#)
- 11:40 Peripheral Lymphedema with Systemic Lymphatic Complications in Childhood: Clinical, Imaging, Genetic Findings, and ISSVA Classification Insights** | [Luisa Ciucci Biagioni \(Brazil\)](#), Jose Luiz Orlando (Brazil), Renata Grizzo Feltrin de Abreu (Brazil), Francisco Ferreira Ramos Junior (Brazil), Dov Charles Goldenberg (Brazil), Raquel Honjo Kawahira (Brazil)
- 11:50 The role of near-infrared fluorescence imaging in the diagnosis and surgical management of lymphatic malformations and chylous disorders** | [Miguel Amore \(Argentina\)](#)
- 12:00 Predicting the Occurrence of Spontaneous Regression for Children with Head and Neck Lymphatic Malformations** | [Juliana Bonilla-Velez \(United States\)](#), Xing Wang (United States), Larry Kessler (United States), Jonathan Perkins (United States), Carrie Heike (United States)
- 12:10 Management of intra-abdominal lymphatic malformations at a tertiary pediatric institution** | [Christine Boone \(United States\)](#), Anne Sailer (United States), Sean Schoeman (United States), Biniyam Tabor (United States), Camryn Krumbhaar (United States), Rosa Hwang (United States), Allison Britt (United States), Tyson Echols (United States), Iris Ortiz-Rivera (United States), Melissa Casey (United States), Pablo Laje

(United States), Peter Mattei (United States), Holly Hedrick (United States), Seth Vatsky (United States), Anne Marie Cahill (United States), Abhay Srinivasan (United States), Denise Adams (United States)

12:20 Maternal Sirolimus Therapy for Fetal Extensive Lymphatic Cystic Malformation: Selection Criteria, Management, and Outcomes in a Series of Six Cases | [Laurent Guibaud \(France\)](#), Marion Bordas-Fournel (France), Alexandre Guilhem (France), Anthony Attalah (France), Alexandra Benachi (France), Marlene Sohler (France), Claudine Le Vaillant (France), Guillaume Canaud (France), Antoine Fraissenon (France)

12:30 Lunch and Posters

12:30-13:30 – Sponsored Lunch Symposium – Palvella

Session 6 – Venous – 14:00-16:00

Moderators: Emmanuel Seront, Reema Padia

14:00 Generation of iPSC-derived human venous organoids for the modeling of venous malformations and drug discovery | [Kai Wang \(China\)](#)

14:10 A Novel Murine Model of TIE2-Driven Venous Malformation | Lindsay Bischoff (United States), Sandra Schrenk (United States), [Elisa Boscolo \(United States\)](#)

14:20 Beyond the Hotspot: MAP3K3 Variant Spectrum in Vascular Anomalies | [Allison Britt \(United States\)](#), Emily Davis (United States), Dong Li (United States), Sarah Sheppard (United States), Özlem Cangir (Germany), Nicolas Eckert (Germany), Friedrich Kapp (Germany), Denny Schanze (Germany), Thomas Scherf (Germany), Martin Zenker (Germany), Megan Corliss (United States), Yang Cao (United States), Catherine Cottrell (United States), Ying-Chen Claire Hou (United States)

14:30 Genetic insights and nomenclature challenges in adult hepatic vascular lesions: a 20-case series and literature review | Lara Rodriguez-Laguna (Spain), [Paloma Triana \(Spain\)](#), Jesús Vicente Redondo-Serrano (Spain), Sara Palencia-Perez (Spain), Juan Carlos Lopez-Gutierrez (Spain)

14:40 Polymeric Rapamycin Nanoparticles Encapsulating Ponatinib Cause Regression of Venous Malformations | Weimin Tang (United States), Ysabel Li (United States), Elise Boscolo (United States), Daniel Kohane (United States), [Kathleen Cullion \(United States\)](#)

14:50 Thrombin-Antithrombin Complex (TAT) as an Early Marker of Post-Sclerotherapy Hypercoagulability in Venous Malformations: A Dynamic Biomarker Analysis | Yingjie Zhu (China), Chaonan Wang (China), Weixin Wang (China), Fengli Jiang (China), Yangze Lv (China), [Hechen Jia \(China\)](#), Xiaonan Yang (China)

15:00 Bone Involvement in Venous Malformation: Spectrum of Various Imaging Patterns | Annouk Bisdorff (France), [Victoire Roblot \(France\)](#)

15:10 Sirolimus for Progressive Colonic Vascular Congestion in an Adolescent Without Detectable Vascular Malformation | [Ramrada Lekwuttikarn \(United States\)](#), David Hovsepian (United States), Joyce Teng (United States)

15:20 Medical Management in Patients with Symptomatic Venous Malformations: A Large Case Series | [Tyson Echols \(United States\)](#), Meg Maguire (United States), Milind Sangani (United States), Allison Britt (United States), Chioma Okuagu (United States), Denise Adams (United States)

15:30 Foam Sclerotherapy for Airway Venous Malformations: Clinical Outcomes and Molecular Background | Artur Medzhidov (Russian Federation), [Lev Voznitsyn \(Russian Federation\)](#)

15:40 Safety and Efficacy of Bleomycin Electrosclerotherapy in Low-Flow Vascular Malformations Resistant to Sclerotherapy: A Prospective Cohort Comparing VGD Straight and Cluster Electrodes | Genti Xhepa (France), Annouk Anne Bisdorff-Bresson (France), Baptiste Bonnet (France), Benoit Faucon (France), Vittorio Civelli (France), Paul Beunon (France), Alexis Ricoeur (Switzerland), Paul Janvier (France), Thierry de Baère (France), Frédéric Deschamps (France), Lambros Tselikas (France)

15:50 Needleless Electrosclerotherapy for Slow-Flow Vascular Malformations of the Pharynx, Palate, and Larynx | Giacomo Colletti (Italy), Linda Rozell-Shannon (United States), Sara Negrello (Italy)

16:00 Break

16:30 Session 7 – Capillary – 16:30-18:00

Moderators: Eulalia Baselga, Ilona Frieden

16:30 Single-vessel transcriptome map pathological landscapes and reveal NR2F2-mediated smooth muscle cell phenotype acquisition in capillary malformations | Vi Nguyen (United States), Irving Mao (United States), Marcelo Hochman (United States), Camilla Wenceslau (United States), J Stuart Nelson (United States), Anil Jegga (United States), Yunguan Wang (United States), Wenbin Tan (United States)

16:40 GNAQ/GNA11 209-induced vascular anomalies: expansion of the clinical phenotype | Flora Bradley (United States), Daniela Kramer (Chile), Giacomo Colletti (Italy), Camila Downey (Chile), Deepti Gupta (United States), Final Patel (United States), Erin Mathes (United States), Taizo Nakano (United States), Ilona Frieden (United States)

16:50 GNAQ-related Overgrowth Spectrum (GROS): A proposal for an updated disease classification | Emma Scott (United States), Akshitha Thatiparthi (United States), Kiran Motaparathi (United States), Michael Lavery (United States)

17:00 A Retrospective Review on GNAQ Somatic Mutations and Associated Phenotypes | Annette Kroes (United States), Allison Britt (United States), Denise Adams (United States), James Treat (United States), Michael Fox (United States), Sally Cohen-Cutler (United States), Kristen Snyder (United States), Alexandre Arkader (United States), Sarah Sheppard (United States), David Low (United States)

17:10 Vasomotors Symptoms : Expanding the Phenotype of GNA11 Capillary Malformations | Olivia Boccara (France), Christine Labrèze (France), Didier Bessis (France), Annabel Maruani (France), Stephanie Mallet (France), Maella Severino (France), Laura Poujade (France), Sébastien Barbarot (France), Anne-Claire Bursztejn (France), Justine Pasteur (France), Astrid Bellissen (France), Thomas Hubiche (France), Pierre Vabres (France), Paul Kuentz (France)

17:20 Pharmacologic activation of PI3K α /AKT in GNAQ p.R183Q endothelial cells reduces endothelial permeability and reduces angiopoietin-2 (ANGPT2) | Sana Nasim (United States), Jill Wylie-Sears (United States), Annegret Holm (United States), Patrick Smits (United States), Arin Greene (United States), Joyce Bischoff (United States)

17:30 Expanding the phenotype spectrum of MAP2K1 variants: Unilateral Skeletal, Vascular, pigmented, and auditory involvement | Bayan Matarneh (United States), Evelyn Ramirez (United States), Vinod Misra (United States), Alison Zarbo (United States)

17:40 Development of a Multimodal Risk Scoring System for Predicting Asymmetric Overgrowth in Limb Capillary Malformations | [Chen Hua](#) (China), Jie Tao (China), Xiaoxi Lin (China)

17:50 Cutis marmorata telangiectatica congenita: an atypical clinical presentation of vascular malformations | Inès El Fekih (France), Sylvie Fraitag (France), Paul Kuentz (France), Amélie Carbonnelle-Puscian (France), Joanne Leborgen de la Villandr  (France), Smail Hadj-Rabia (France), [Olivia Boccara](#) (France)

19:00 – 22:00 – ISSVA Social Event – Offsite – Reading Terminal Market (across the street from the venue) **Tickets required

22 May 2026 – Scientific Sessions

Session 8 - Other Studies II – 8:00-10:00

Moderators: Adrienne Hammill, Ionela Iacobas

8:00 Utility of a Swine Animal Model for Testing the Chondrotoxicity Potential of Sclerosing Agents | [Jennifer Mayer](#) (United States), Christopher Francis (United States), Hector Monforte (United States), Rebecca Krimins (United States), Cory Brayton (United States), Jessica Izzi (United States), Ernest Amankwah (United States), Junko Sawada (United States), Cassandra Moats (United States), Cierra Streaker (United States), Sally Mitchell (United States)

8:10 Co-Expression of Histone Lysine Methyl Transferases and PIK3 Mutations in Vascular Anomalies | Emily Robbins (United States), Mona Nourani (United States), Alok Kothari (United States), Carrie Schaefer (United States), Scott Willard (United States), Harper Price (United States), [David Carpentieri](#) (United States)

8:20 Droplet Digital PCR as a First-Line Detection Tool in the Genetic Diagnosis of Vascular Anomalies | [Tara Lane](#) (Australia), Timothy Green (Australia), Denisse Garza (Australia), Natasha Brown (Australia), Michelle de Silva (Australia), Mark Bennett (Australia), Caitlin Tubb (Australia), Roderic Phillips (Australia), Susan Robertson (Australia), Phillip Bekhor (Australia), Jodie Simpson (Australia), Anthony Penington (Australia), Michael Hildebrand (Australia)

8:30 If at first you don't succeed, try try again : The value of iterative genetic testing in patients with vascular anomalies | Leonid Yermakov (United States), Cate Paschal (United States), Jaya Narayanan (United States), Larissa Rogge (United States), Will Tobin (United States), Kylie Nelson (United States), Louisa Emery (United States), Susan Schowalter (United States), James Bennett (United States), [Nya Nelson](#) (United States)

8:40 Prevalence and Clinical Impact of Dysphagia in Pediatric Lymphatic Malformations: A Retrospective Cohort Study | [Maha Alsomali](#) (United States), Jb Jb Eyring (United States), Fred Grimmer (United States), Reema Padia (United States)

8:50 Alpelisib for vascular anomalies beyond PROS: evidence of efficacy for diverse genotypes and phenotypes | [Deeti Pithadia](#) (United States), Marina Heskel (United States), Patricia Cornett (United States), Arman Shotayev (United States), Sunit Davda (United States), Rachelle Durand (United States), Daniel Cooke (United States),

Josephine Czechowicz (United States), Mary Lesh (United States), Kristin Shimano (United States), Erin Mathes (United States), Ilona Frieden (United States), Beth Apsel Winger (United States)

9:00 Everolimus is a safe and effective alternative to sirolimus in patients with complex vascular anomalies | [Annegret Holm \(United States\)](#), Sandra Schrenk (United States), Anne Groteklaes (Germany), Claudia Blattmann (Germany), Ines Brecht (Germany), Etelka Foeldi (Germany), Martin Zenker (Switzerland), Elisa Boscolo (United States), Jochen Roessler (Switzerland), Denise Adams (United States), Whitney Eng (United States), Friedrich Kapp (Germany)

9:10 Transperineal approach technique for the treatment of slow-flow perirectal vascular malformations. | Mayra Velarde Castillo (Mexico), [Alejandro Celis Jimenez \(Mexico\)](#), Michel Avila (Mexico)

9:20 Topical Timolol for Residual Infantile Hemangiomas in Children Aged 1-5 Years with Psychosocial Distress: A Justified Option Beyond Infancy | Olga Bogomolets (Ukraine), [Iryna Benzar \(Ukraine\)](#)

9:30 Click, Learn, Treat: Developing an On-Demand Multispecialty Hub for Vascular Anomalies Education | [Joana Mack \(United States\)](#), Andrew Tran (United States), Taizo Nakano (United States), Meghan McCormick (United States), Irina Pateva (United States), Bhuvana Setty (United States), David Becton (United States), Shelley Crary (United States)

9:40 Defining and recording Patient Centered Goals of Treatment in a multidisciplinary vascular anomalies clinic. | [Tony Penington \(Australia\)](#), Jodie Simpson (Australia), Lydia Pathmanathan (Australia), Rod Phillips (Australia)

9:50 Reproductive and pregnancy outcomes following treatment with sirolimus for vascular malformations | [Emmanuel Seront \(Belgium\)](#), An Van Damme (Belgium), Annouk Bisdorff-Bresson (France), Anne Domp Martin (France), Rune Andersen (Norway), Miikka Vikkula (Belgium), Laurence Boon (Belgium)

10:00 Break

Session 9 – Combined – 10:30-12:30

Moderators: Alan Irvine, Michio Ozeki

10:30 Leveraging microphysiological models of vascular malformations to screen novel therapeutic approaches | [William Polacheck \(United States\)](#)

10:40 A diagnostic workflow for spatially-guided sequencing in vascular anomalies enabled by non-destructive 3D histopathology | [René Hagerling \(Germany\)](#)

10:50 Expanding the Phenotypic Spectrum of KRAS-Associated Vascular Malformations: Two Contrasting Cases | [Will Swansson \(Australia\)](#), Ingrid Winship (Australia), Jessica McClatchy (Australia), Laura Scardamaglia (Australia)

11:00 Gorham Stout Disease with a Somatic BRAF Variant Responding to Combined Sirolimus and Trametinib Therapy | [Michael Briones \(United States\)](#), Jay Shah (United States), Michael Leshen (United States), Michael March (United States), Michael White (United States), Janette Dimonda (United States), Rossana Sanchez (United States), Alyssa Kessleman (United States), Matthew Hawkins (United States), Annie Gill (United States), Banu Karatas (United States), Hakon Hakonarson (United States), Dong Li (United States)

11:10 Zovegalisib (RLY-2608), a novel, mutant-selective, PI3Ka inhibitor, induces lesion regression, with minimal hyperinsulinemia, in murine models of PIK3CA-mutant

vascular malformations | [Mariona Graupera \(Spain\)](#), Maria Garrido (Spain), Ariadna Roca (Spain), Ana Angulo-Urarte (Spain), Sweta Swaminathan (United States), Amanda Iskandar (United States), Matthew S. Crowe (United States), Fabien Llambi (United States), Ermira Pazolli (United States), James Watters (United States), Brenton G. Mar (United States)

11:20 PIK'ing Apart Vascular Malformations: Genetic Testing in Overgrowth Syndromes | Tien Do (United States), Anthony Basta (United States), Mallika Singh (United States), [Kelly Ruygrok \(United States\)](#), Denisse Leza-Rincon (United States), Charles Cox (United States), Adelaide Hebert (United States), Kate Richardson (United States), Autumn Atkinson (United States), Matthew Greives (United States)

11:30 Serum D-2-hydroxyglutarate: a non-invasive diagnostic tool for Maffucci syndrome over Ollier disease | Victor Viala (France), [Annouk Bisdorff-Bresson \(France\)](#), Lauriane Goldwirt (France), Emmanuel Mandonnet (France), Thomas Funck-Brenatano (France)

11:40 Portal venous thrombosis associated with colorectal venous malformations in patients with PIK3CA-related overgrowth spectrum. | [Mariya Kristeva \(United States\)](#), Ahmad Alomari (United States), Josee Dubois (United States), Steven Fishman (United States), Kyung Kim (United States), Tiana McCann (United States), Raja Shaikh (United States)

11:50 Evaluating Safety and Efficacy of Trametinib in Patients with Noonan Syndrome and Lymphatic Disorders | [Sumukh Kumar \(United States\)](#), Allison Britt (United States), Vanessa Bustard (United States), Yoav Dori (United States), Erin Pinto (United States), Christopher Smith (United States), Michael Fox (United States), Sally Cohen-Cutler (United States), Denise Adams (United States)

12:00 A Tracheostomy-Free Approach to Airway-Involving Low-Flow Vascular Malformations: Elective Prolonged Intubation and Percutaneous Sclerotherapy | [Dario Teplisky \(Argentina\)](#), Ignacio Formia (Argentina), Melisa Díaz Galdeano (Argentina), Sergio Sierre (Argentina)

12:10 Management of patients with localized low-flow malformations in the gluteal region | [Paolo Gasparella \(Austria\)](#), Christina Flucher (Austria), Margarita Eibisberger (Austria), Stephan Spendel (Austria), Emir Q Haxhija (Austria)

12:20 Short-Term Outcomes with Surgical Treatment of Peri- and Intra-Articular Vascular Anomalies | Raylin Xu (United States), Winnie Lin (United States), [Samantha Spencer \(United States\)](#)

12:30 Lunch and Posters

12:45-14:45 – NAVAP (Nursing and Administration of Vascular Anomalies Programs) Meeting

Session 10 - Difficult Cases – 14:00-16:00

Moderators: Dov Goldenberg, Par Gerwins

14:00 Identification of a de novo variant in GABPα in a patient with multiple vascular tumors of an unclassified entity | [Annegret Holm \(United States\)](#), Pascal Brouillard (Belgium), Mehrnaz Mehrabipour (United States), Harry Kozakewich (United States), John Mulliken (United States), Miikka Vikkula (Belgium), Joyce Bischoff (United States)

14:10 Diagnostic Evolution in a Complex Vascular Anomaly: A Nine-Year Journey from Kaposiform hemangioendothelioma to Suspected Kaposiform lymphangiomatosis | [Lynette Wee \(Singapore\)](#), Yishan Ang (Singapore), Shiao Wei Quah (Malaysia), Luke Toh (Singapore), Ze Hao Tan (Singapore), Mark Koh (Singapore)

14:20 Facial capillary malformation with dural sinus malformation and arteriovenous

- fistula (CAMS II): endovascular diagnosis and treatment** | Alberto Alvarez-Muelas (Spain), Paloma Triana (Spain), Pedro Navia (Spain), Andres Javier Barrios (Spain), Clara Venegas (Spain), Lara Rodriguez-Laguna (Spain), Javier Saceda (Spain), Juan Carlos Lopez-Gutierrez (Spain), Andres Fernandez-Prieto (Spain)
- 14:30 Navigating Treatment without a Molecular Target: Complex lymphatic anomaly with extensive osseous involvement in a pediatric patient** | C. Matthew Hawkins (United States), Jill Flanagan (United States), Rossana Sanchez (United States), Alyssa Kesselman (United States), Janette DiMonda (United States), Anne Gill (United States), Michael Briones (United States)
- 14:40 Ex-situ mesenteric resection of a venolymphatic malformation and autotransplantation** | Edith Klappe (Netherlands), Barbara Sjouke (Netherlands), Bas Verhoeven (Netherlands), Bastiaan Klarenbeek (Netherlands), Floris Kroezen (Netherlands), Sijbrand Hofker (Netherlands)
- 14:50 Sirolimus and Pregnancy: A Vascular Anomaly Success Story** | Rachel Mayo (United States), Shelley Crary (United States), Joana Mack (United States)
- 15:00 Prenatal Sirolimus - 2 year follow up case** | Autumn Atkinson (United States), Sarah McDermott (United States), Kelly Ruygrok (United States), Adelaide Hebert (United States), Matthew Greives (United States)
- 15:10 Refractory Anemia in CLOVES Syndrome** | Jiejun Xia (China), Haibo Li (China), Zhenyin Liu (China)
- 15:20 18-month-old male presenting with partial paraplegia** | Daniel M Balkin (United States), Daniela M Guerrero Mullix (United States), Emily Meara (United States), Sri Harshavardhan Malapati (United States), Katie P Fehnel (United States), Darren B Orbach (United States), John B Mulliken (United States), Marilyn G Liang (United States)
- 15:30 En face margin assessment in cutaneous arteriovenous malformations of the face: a novel approach.** | Maha Alsomali (United States), Angelica Putnam (United States), Reema Padia (United States), Fred Grimmer (United States), Alice Frigerio (United States)
- 15:40 Intracranial arteriovenous malformation with excellent response to alpelisib** | Marina Heskel (United States), Daniel Cooke (United States), Ethan Winkler (United States), Deeti Pithadia (United States), Beth Apsel Winger (United States), Patricia Cornett (United States)
- 15:50 Multimodal Endovascular Treatment of a Complex Recurrent Auricular Vascular Anomaly with Targeted Embolization and Laser Ablation** | Enmanuel Guillermo de la Cruz (Mexico), Carlo Angello Sanchez Montaño (Mexico), Maria Fernanda Ortega Trevino (Mexico), Enrique Mañon Ferreyra (Mexico), Andrea Carolina Falconi Paez (Mexico), Edgar Calderon Venegas (Mexico), Rafael Jimenez Vazquez (Mexico), Juan Miguel Rodriguez Trejo (Mexico), Neftali Rodriguez Ramirez (Mexico)
- 16:00 Closing Ceremony**

Social Programs (in-person only)

Welcome Reception

We invite all in-person attendees to the Welcome Reception, which will take place in Franklin B on Tuesday, 19 May, from 18:00 - 19:30, immediately following the Primer Day Sessions. There will be light appetizers and drinks available, as well as the opportunity to network with colleagues and visit the Exhibition Hall. Everyone will receive one drink ticket for the reception; you are welcome to purchase additional beverages after that.

Tuesday, 19 May • 18:00 - 19:30

Location: Franklin B

Congress Social Event

Join colleagues for an evening of celebrating the ISSVA World Congress 2026

The Social Event requires a ticket to attend. If available, extra tickets will be available at the Registration Desk onsite (there are a limited number of tickets).

Thursday, 21 May • 19:00 – 22:00 PM

Location: Reading Terminal Market (across the street from the venue)

Running Club

The ISSVA Running Club will be meeting on the morning of Friday 22 May for a casual run. To join the Running Club, we request a donation to the ISSVA Education Fund.

Friday, 22 May • 6:30-7:15am

Meet at: Hotel Lobby (near the reception desk)

Classification Session, Non-CME Symposia & Affiliate Meetings (In-Person Only)

ISSVA Classification Session

Join us for a session to discuss the ISSVA Classification.

13:00 – 13:45 pm | May 19, 2026

Salon CD

Topics discussed: History of the classification, updating the classification and upcoming updates. A discussion will follow.

Non-CME Sponsored Symposia

Relay Therapeutics Breakfast Symposium (Gold Sponsor)

7:00 – 8:00 am | May 20, 2026

Salon CD

Novartis Lunch Symposium (Gold Sponsor)

12:35 – 13:35 pm | May 20, 2026

Salon CD

Protara Therapeutics Breakfast Symposium

7:00 – 8:00am | May 21, 2026

Salon CD

Palvella Therapeutics Lunch Symposium (Platinum Sponsor)

12:30 – 13:30 | May 21, 2026

Salon CD

Affiliate Meetings (In-person)

Nursing and Administration of Vascular Anomaly Programs (NAVAP) Committee Meeting

12:45 – 14:45 | May 22, 2026

Meeting Room 403

NAVAP will be hosting its first official meeting, and all coordinators are welcome to join. Pick up your lunch in Franklin B, then join the meeting.

Sponsors

The International Society for the Study of Vascular Anomalies would like to thank the following for their support.

Platinum Sponsor:



Gold Sponsors:



Bronze Sponsor:



Other Sponsors & Exhibitors:



The ISSVA World Congress 2026 is also Supported by an Educational Grant from Guerbet LLC.